Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Vancouver biotech Zymeworks closes US$929M Theravance deal

24 September 2026 · By · Wire by Fusion42

Published

24 September 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

Canada

◆ Source

Read at biv.com →

◆ Verified

Fusion42 · 25 September 2026 · Fusion42 review

Vancouver-based biotech Zymeworks completed its acquisition of Theravance Biopharma for approximately US$929 million, diversifying its portfolio beyond cancer treatments to include commercial, royalty, and drug-development assets, notably the COPD drug Yupelri.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a more competitive biotech market after Zymeworks' big bet beyond cancer drugs with Theravance. This deal opens new commercial pathways beyond oncology if your startup targets respiratory or neurological treatments.

◆ Coverage

1 source · 24 Sep 2026

◆ Related on Wire

◆ Topics

Biotechbiotechacquisitionportfolio-diversificationtheravancezymeworkscopd